207 related articles for article (PubMed ID: 17785939)
21. Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization.
Odening KE; Hyder O; Chaves L; Schofield L; Brunner M; Kirk M; Zehender M; Peng X; Koren G
Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2264-72. PubMed ID: 18835916
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
23. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
24. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
25. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
[TBL] [Abstract][Full Text] [Related]
27. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.
Webster R; Allan G; Anto-Awuakye K; Harrison A; Kidd T; Leishman D; Phipps J; Walker D
Xenobiotica; 2001; 31(8-9):633-50. PubMed ID: 11569530
[TBL] [Abstract][Full Text] [Related]
29. Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
Abdelhady AM; Shugg T; Thong N; Lu JB; Kreutz Y; Jaynes HA; Robarge JD; Tisdale JE; Desta Z; Overholser BR
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1206-1213. PubMed ID: 27333947
[TBL] [Abstract][Full Text] [Related]
30. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
[TBL] [Abstract][Full Text] [Related]
31. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
32. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
[TBL] [Abstract][Full Text] [Related]
33. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
Qu Y; Fang M; Gao B; Chui RW; Vargas HM
J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
[TBL] [Abstract][Full Text] [Related]
34. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
Cheng HC; Incardona J
J Pharmacol Toxicol Methods; 2009; 60(2):174-84. PubMed ID: 19524054
[TBL] [Abstract][Full Text] [Related]
35. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Wang WQ; Robertson C; Dhalla AK; Belardinelli L
J Pharmacol Exp Ther; 2008 Jun; 325(3):875-81. PubMed ID: 18322148
[TBL] [Abstract][Full Text] [Related]
36. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
37. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
38. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs.
Ozaki K; Sudo H; Muramatsu H; Yogo K; Kamei K; Koga H; Itoh Z; Omura S; Takanashi H
Inflammopharmacology; 2007 Feb; 15(1):36-42. PubMed ID: 17323194
[TBL] [Abstract][Full Text] [Related]
39. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Wu L; Rajamani S; Li H; January CT; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1048-57. PubMed ID: 19592609
[TBL] [Abstract][Full Text] [Related]
40. Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.
Sugiyama A; Satoh Y; Takahara A; Nakamura Y; Shimizu-Sasamata M; Sato S; Miyata K; Hashimoto K
Eur J Pharmacol; 2003 Apr; 466(1-2):137-46. PubMed ID: 12679150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
